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SObjectives: Sleeve lobectomy was introduced for patients with lung cancer whose pulmonary reserve was in-
adequate for pneumonectomy. However, the safety and survival benefits of wedge bronchoplastic lobectomy as
an alternative to sleeve lobectomy have not been thoroughly studied. This study was performed to evaluate the
safety and oncologic results of wedge bronchoplastic lobectomy for lung cancer.
Methods:We retrospectively analyzed 191 patients who underwent wedge bronchoplastic lobectomy and me-
diastinal lymph node dissection from 2001 to 2009.
Results: There were 174 male patients with a mean age of 61.8 8.2 years. The median follow-up duration was
28months. Nine patients showed severe postoperative complications: bronchopleural fistulas (n¼ 3), necrosis at
the bronchoplasty site (n¼ 1), or obstruction (n¼ 5). The operative mortality rate was 3.7%. Local and regional
recurrences were reported in 17 and 12 patients, respectively. The 5-year overall survival was 62.8%. The 5-year
overall survival was 68.6% in N0, 64.4% in N1, and 52.6% in N2 (P¼ .09). The 5-year overall freedoms from
local recurrence and locoregional recurrence were 85.3% and 78.9%, respectively, which did not differ by nodal
status. A multivariate analysis showed that positive N1 and N2 nodes were risk factors (P ¼ .036 and P ¼ .042,
respectively) for overall survival after wedge bronchoplastic lobectomy.
Conclusions: Wedge bronchoplastic lobectomy for lung cancer is a safe and feasible procedure that does not
compromise oncologic principles. It can be considered an appropriate alternative to sleeve lobectomy and pneu-
monectomy, regardless of nodal status. (J Thorac Cardiovasc Surg 2012;143:825-31)Earn CME credits at
http://cme.ctsnetjournals.orgSupplemental material is available online.
Bronchoplastic procedures were initially introduced as al-
ternative procedures for patients with lung cancer whose
pulmonary reserve was thought to be inadequate for tolerat-
ing pneumonectomy; it has now become the standard proce-
dure, regardless of the patient’s functional status. There are
3 types of bronchoplastic procedures: sleeve lobectomy,
flap bronchoplasty, and wedge bronchoplasty.1 Several re-
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The Journal of Thoracic and Caadvantages over pneumonectomy in terms of operativemor-
bidity, mortality, and long-term oncologic results.2-4 After
sleeve lobectomy, however, the circumferential resection
of the bronchus and the intraoperative interruption of the
bronchial vascular supply to the distal bronchial segment
can result in ischemia at the anastomosis site and
subsequent devastating complications, such as bronchial
strictures or bronchopleural fistulas (BPFs).5 Approxi-
mately 2.3% to 5% of patients have bronchial strictures af-
ter sleeve lobectomy and 2% to 6.9% of patients have
BPFs.6
Rather than circumferentially resecting the bronchus,
wedge bronchoplastic lobectomy resects in a wedge shape
and reanastomizes it. This procedure can preserve the blood
supply to the distal bronchus and subsequently reduce the
ischemia at the anastomotic site and prevent circumferential
strictures. Kr€uger and associates7 reported a significantly
higher rate of major anastomotic complications and
pneumonias after sleeve lobectomy than after wedge bron-
choplasty. Despite these merits, wedge bronchoplastic
lobectomies have not been extensively performed by tho-
racic surgeons, in some cases because many surgeons think
that both tumor and nodal clearance are less satisfactory
with wedge bronchoplastic lobectomy than they are with
sleeve lobectomy.5 Also, Khargi and coworkers1 have re-
ported that anastomotic complications, such as bronchial
stenosis, frequently developed after wedge bronchoplastic
lobectomy. Furthermore, there have been few studiesrdiovascular Surgery c Volume 143, Number 4 825
TABLE 1. General characteristics of the patients
Variables No. (%)
Age (y) 61.8  8.2
Gender (male/female) 174 (91.9%)/17 (8.9%)
Preoperative chemotherapy 24 (12.6%)
Location of lesion
RUL 93 (48.7%)
RML 14 (7.3%)
RLL 25 (13.1%)
RULþRML 3 (1.6%)
RMLþRLL 1 (0.5%)
LUL 37 (19.4%)
LLL 18 (9.4%)
Nodal status
N0 67 (35.1%)
N1 81 (42.4%)
N2 43 (22.5%)
Pathologic stage*
I 40 (20.9%)
II 80 (41.9%)
III 71 (37.2%)
Pathologic cell type
Squamous cell carcinoma 153 (80.1%)
Adenocarcinoma 21 (10.9%)
Others 17 (9.0%)
Pulmonary angioplasty 16 (8.4%)
Operative time (min) 232.9  69.5
Hospital days (d) 14.6  10.5
Operative mortality 7 (3.7%)
Postoperative chemotherapy 66 (34.6%)
Postoperative radiotherapy 15 (7.9%)
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left up-
per lobe; LLL, left lower lobe. *American Joint Committee on Cancer 2010 lung can-
cer stage.
Abbreviations and Acronyms
BPF ¼ bronchopleural fistula
BVF ¼ bronchovascular fistula
CI ¼ confidence interval
CIS ¼ carcinoma in situ
NSCLC ¼ non–small cell lung cancer
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Sexamining the long-term oncologic and survival outcomes
of wedge bronchoplastic lobectomies.1,8
At our institution, wedge bronchoplastic lobectomy has
been performed as an alternative procedure to sleeve lobec-
tomy in cases of non–small cell lung cancer (NSCLC) in-
volving or protruding into the main bronchus. Therefore,
our experience provides a unique opportunity to evaluate
the procedure’s safety and long-term survival, focusing on
locoregional recurrences. This evaluation was the main pur-
pose of our study.
METHODS
Patients
This retrospective study was approved by the institutional review board
of the hospital (IRB No. NCCNCS-10-419). We retrospectively reviewed
medical and surgical records and bronchoscopic findings. One hundred
ninety-one patients who underwent wedge bronchoplastic lobectomies
with complete mediastinal lymph dissection for NSCLC between March
2001 and January 2009 were enrolled. All tumors invading or protruding
at the orifice of the main bronchus were indicated for wedge bronchoplasty
lobectomy. During the same period, 43 cases of sleeve lobectomywere per-
formed at the same institution (Figure E1). In 14 (32.5%) of 43 cases, how-
ever, wedge bronchoplastic lobectomy was considered first, but we
eventually had to perform sleeve lobectomy because a sufficient resection
margin could not be obtained by wedge bronchoplasty, despite multiple
frozen sections.
The general characteristics of the patients are shown in Table 1. The me-
dian follow-up period was 28months (range, 0.8-91.5 months). Chest com-
puted tomography, positron emission tomography, bronchoscopy, and
pulmonary function testing were performed preoperatively. Bronchoscopic
inspection has been routinely performed on postoperative day 7 since 2006.
Until 2005, a bronchoscopic inspection was performed when surgical mor-
bidities, such as stenosis, fistulas, or distortions, were clinically suspected.
Adjuvant chemotherapy was considered in patients with nodal metastasis
and adjuvant radiotherapy was considered when the resection margin
was above the dysplasia on the permanent pathologic report and the patient
could medically tolerate it. Postoperative chest computed tomographic
scans were obtained at 3-month intervals, and positron emission tomo-
graphic scans were obtained annually to detect recurrences.
Local recurrences were defined as those occurring on the bronchial re-
section margins and airways, such as the bronchial stumps, bronchi, carina,
or trachea. Regional recurrences were defined as those occurring in the hilar
or mediastinal lymph nodes and the pleural cavity. Distant recurrences were
defined as those occurring in the lung, brain, liver, adrenal glands, bones,
and other locations. An R1 resection of the bronchial margin was defined
as carcinoma in situ (CIS) or invasive carcinoma at the bronchial margin.9
Surgical Technique
The indication for wedge bronchoplastic lobectomywas the presence on
preoperative bronchoscopy of endobronchial lesions that had invaded or826 The Journal of Thoracic and Cardiovascular Surgprotruded into the main bronchus; therefore, conventional stapling devices
could not be applied for the bronchial resection. The lungs were ventilated
with a double-lumen tube in all patients. A standard posterolateral thora-
cotomy was performed in the lateral decubitus position. The pleural space
was entered through the fifth intercostal space. After dissection of the intra-
pulmonary ligament, the pulmonary vein and lobar pulmonary arteries
were transected, and a complete mediastinal lymph node dissection was
performed. The systemic blood supply via the bronchial artery was pre-
served as much as possible. The tumor was palpated, and a bronchotomy
was performed to assess the precise intraluminal tumor location. The af-
fected lung lobe and a portion of the main bronchus were excised through
2 oblique bronchial incisions in the main bronchus (a wedge resection), in
contrast to circumferential resection of the bronchus in sleeve lobectomy
(Figure 1, A). In this way, over half the circumference of the main bronchus
was excised and trimmed. After the negative resection margins had been
confirmed by frozen pathologic examination, the bronchial edges were ap-
proximated or plicated. The cartilaginous part was sutured with interrupted
or figure-of-8 4-0 PDS polydioxanone sutures (Ethicon, Inc, Somerville,
NJ). After the anastomosis was completed, an intraoperative bronchoscopic
inspection was performed to evaluate it. The anastomosis was covered with
pedicled pericardial fat or a pleural flap in all the patients. In some cases,
pericardial release was performed to reduce the tension on the suture
line. A schematic illustration of a wedge bronchoplastic lobectomy is
shown in Figure 1, B. Figure 1, C, shows a 3-dimensional computed tomo-
graphic reconstruction image after a wedge bronchoplastic right upper lo-
bectomy, with the remainder of the bronchus folded outside.ery c April 2012
FIGURE 1. An extensive wedge bronchoplastic lobectomy. A, The intraoperative findings for a wedge bronchoplastic right upper lobectomy. The right
upper lobe bronchus and bronchus intermedius were resected into a wedge shape. B, A schematic illustration of a wedge bronchoplastic lobectomy. After
the wedge resection of the bronchus, the right upper lobe was removed, and the remnant bronchus was closed. To prevent folding of the remainder of the
bronchus into the lumen of the bronchus, additional sutures can be added to the remainder of bronchus. C, A 3-dimensional reconstruction image after
a wedge bronchoplastic right upper lobectomy. The remainder of the bronchus (arrow at the plication site) was folded outside the lumen of the bronchus.
In this case, the folded bronchus did not result in narrowing of the bronchial lumen. SVC, Superior vena cava; RML, right middle lobe; RLL, right lower lobe;
BI, bronchus intermedius.
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The findings of the bronchoscopic inspection on postoperative day 7
were classified into 4 categories of complications: normal, mild, moderate,
and severe (Figure E2). Mild complications were defined as erythema or
edema, without luminal narrowing at the bronchoplasty site. After the re-
section of the bronchus and anastomosis, the remainder of the bronchus
could, in some cases, fold into or outside the lumen of the bronchus. An
‘‘inner-fold’’ was defined as having this inner folding into the lumen. Mod-
erate complications were defined as this inner folding or as mild ischemia
with mild luminal narrowing but without narrowing-related complications,
such as obstructive pneumonia or dyspnea. Severe complications were de-
fined as severe ischemia, BPFs, total obstruction, or necrosis at the bron-
choplasty site.
Statistical Analysis
Statistical analysis was performed using STATA 11 software (Stata
Corp, Stata Statistical Software, Release 11 [2005], College Station,
Tex). Patient survival was analyzed using the date of the procedure
as the starting point, and the Kaplan-Meier method was used to estimate
the survival. The log–rank test was used to compare the survival in the
univariate analysis. A Cox proportional hazard model with backward
variable selection at a significance level of .05 was used for the multivariate
analysis.RESULTS
Pathologic Results of Resection Margin
In the frozen pathologic reports, 184 patients had nega-
tive margins, 4 (2.1%) patients had dysplasia, and 3
(1.6%) patients had CIS. In the permanent pathologicThe Journal of Thoracic and Careports, however, 175 (91.1%) patients showed a negative
resection margin. Two (1.0%) patients were reported as
having metaplasia, and 6 (3.1%) patients were reported as
having dysplasia. An R1 resection was reported in 8
(4.2%) patients: 7 (3.7%) with CIS and 1 (0.5%) with in-
vasive carcinoma. Of these 8 patients, 5 had a diagnosis
of negative resection margins, 1 had a diagnosis of dyspla-
sia, and 2 had a diagnosis of CIS on the frozen pathologic
report (Table E1).
Of the 14 patients given a diagnosis of dysplasia, CIS, or
invasive carcinoma, 2 had local recurrence and 5 had
distant metastasis. Postoperative radiotherapy was per-
formed in 3 of these 14 patients, and they did not have local
recurrence. The outcomes for these patients are summarized
in Figure E3.
Bronchoscopic Follow-up After Wedge
Bronchoplastic Lobectomy
A postoperative bronchoscopic follow-up was performed
in 95 (49.7%) patients. The 96 patients who did not undergo
bronchoscopic follow-ups showed no clinical evidence of
complications. Among the 95 patients with bronchoscopic
follow-up who did undergo follow-up, 37 patients had
normal bronchoscopic findings. Overall, 15 patients experi-
enced mild complications, 34 had moderate complications,
and 9 patients had severe complications, such as BPFsrdiovascular Surgery c Volume 143, Number 4 827
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ischemia (n ¼ 5). The severe ischemic lesions at the bron-
choplasty site eventually led to total obstruction on the
follow-up bronchoscopy.Surgical Morbidities and Mortalities
Of the common complications of wedge bronchoplastic
lobectomy, sputum retention requiring bronchoscopic toi-
leting and atelectasis developed in 28 (14.7%) patients.
Lung injuries, such as acute lung injuries or acute respi-
ratory distress syndrome, developed in 8 (4.2%) patients.
Of the 3 patients who had BPFs, 2 recovered with conser-
vative treatment, and 1 underwent the Eloesser procedure
owing to BPF-related empyema. Necrosis at the broncho-
plasty site developed in 1 patient, and he underwent com-
pletion pneumonectomy owing to superimposed fungal
infection. Five (2.6%) patients had significant narrowing
and near total obstruction at the bronchoplasty site. Of
them, 2 patients received repeated bronchoscopic balloon
dilatation with argon plasma coagulation therapy. Three
patients did not receive further treatment for narrowing
or obstruction because they did not have clinical symp-
toms, such as dyspnea or obstructive pneumonia. Bron-
chovascular fistulas (BVFs) did not develop in this
patient series. The operative mortality rate was 3.7% (7
cases), with the following causes: acute myocardial
infarction (n ¼ 1), postoperative pneumonia (n ¼ 1),
and acute respiratory distress syndrome (n ¼ 5). The
mortality case of the postoperative pneumonia was related
to BPF.FIGURE 2. Survival curves. A, Overall survival according to nodal status.
B, Freedom from local recurrence according to nodal status. C, Freedom
from locoregional recurrence according to nodal status. CI, Confidence in-
tervals.Patterns of Recurrence and Survival
Recurrence was reported in 59 patients, with 17 local re-
currences (10 in the stump and 7 in the trachea or carina),
12 regional recurrences (7 pleural or chest wall masses
and 5 mediastinal lymph nodes), and 43 distant recurrences
(17 lung, 8 brain, 6 liver, 7 bone, 2 adrenal glands, and 10
other). Seven patients had multiple distant recurrences.
Four patients had both local and distant recurrences, and
9 patients had both regional and distant recurrences. Two
patients had double primary lung cancer after the operation.
The 5-year overall survival after wedge bronchoplastic
lobectomy was 62.8% (95% confidence interval [CI],
49.9%73.2%), and the 5-year disease-free survival was
50.0% (95% CI, 40.4%58.8%). According to the
Kaplan-Meier analysis, the 5-year overall survival was
68.6% (95% CI, 38.5%86.1%) in the N0 cases, 64.4%
(95% CI, 49.8%75.7%) in the N1 cases, and 52.6%
(95% CI, 26.9%73.0%) in the N2 cases (P ¼ .09 for
the log–rank test; Figure 2, A). The 5-year overall survival
was 60.6% (95%CI, 46.6%71.9%) in the patients whose
resection margins were negative or who had metaplasia
and 84.6% (95% CI, 50.4%95.9%) in the patients with828 The Journal of Thoracic and Cardiovascular Surgdysplasia, CIS, or carcinoma (P ¼ .342 for the log–rank
test).
The 5-year overall rate for freedom from local recurrence
was 85.3% (95% CI, 75.8%91.2%), and the 5-yearery c April 2012
TABLE 2. The risk factors for overall survival after wedge bronchoplastic lobectomy using a Cox proportional hazard model
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.039 (0.998-1.082) .062 — —
Gender (male vs female) 2.112 (0.511-8.727) .302 — —
Preoperative chemotherapy 1.628 (0.723-3.662) .239 — —
T stage
T2 (vs T1) 1.802 (0.777-4.176) .170 — —
T3 (vs T1) 1.630 (0.602-4.417) .337 — —
T4 (vs T1) 2.256 (0.658-7.732) .196 — —
Nodal status (N stage)
N1 (vs N0) 2.203 (1.019-4.763) .045 2.311 (1.0575.051) .036
N2 (vs N0) 2.241 (0.958-5.244) .063 2.426 (1.0325.701) .042
Resection margins (above the dysplasia) 0.509 (0.123-2.105) .351 — —
Concomitant pulmonary angioplasty 1.710 (0.724-4.042) .221 — —
Severe bronchial complications 0.622 (0.085-4.531) .639 — —
Postoperative chemotherapy 1.600 (0.884-2.897) .120 1.778 (0.9783.233) .059
Postoperative radiotherapy 0.606 (0.226-2.377) .734 — —
Only the variables that were selected via backward variable selection at a significance threshold of 0.05 in the multivariate analysis are listed. HR, Hazard ratio; CI, confidence
intervals.
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(95% CI, 69.6%85.7%). The 5-year overall freedom
from local recurrence was 88.6% (95% CI, 73.8%
95.2%) in the N0 cases, 80.2% (95% CI, 59.2%
91.1%) in the N1 cases, and 88.8% (95% CI, 72.7%
95.6%) in the N2 cases (P ¼ .757; Figure 2, B). The 5-
year freedom from locoregional recurrence was 85.4%
(95% CI, 71.1%92.9%) in the N0 cases, 72.3% (95%
CI, 53.5%92.9%) in the N1 cases, and 80.3% (95%
CI, 62.9%90.1%) in the N2 cases (P ¼ .433; Figure 2,
C). There were no significant differences in freedom from
local and locoregional recurrence based on nodal status.
Risk Factors for Overall Survival After Wedge
Bronchoplastic Lobectomy
Age, sex, preoperative chemotherapy, T stage, N stage
(nodal status), resection margins (dysplasia, CIS, and car-
cinoma vs negative for cancer and metaplasia in the
permanent resection margins), concomitant pulmonary
angioplasty, severe postoperative complications, postopera-
tive chemotherapy, and radiotherapy were included in using
the Cox proportional hazards model (Table 2). In the univar-
iate analysis, N1 was a significant risk factor when com-
pared with N0 (P ¼ .045), and age (P ¼ .062) and N2,
compared with N0 (P ¼ .063), were marginally significant.
In the multivariate analysis, N1 (P ¼ .036) and N2
(P ¼ .042) compared with N0 were significant risk factors
for overall survival after wedge bronchoplastic lobectomy.
Positive resection margins and concomitant pulmonary an-
gioplasty were not related to overall survival in this analysis.
DISCUSSION
This study demonstrates that wedge bronchoplastic lo-
bectomy for lung cancer has acceptable complications andThe Journal of Thoracic and Caoncologic results. The incidence of local and regional recur-
rence is at the center of the debate regarding the long-term
results of sleeve lobectomy versus pneumonectomy. Local
disease control is one of the main goals of surgical resection
for lung cancer.10 Some surgeons believe that if the tumor
cells involve the peribronchial lymphatics in N1 or N2 dis-
ease, then sleeve lobectomy may increase the incidence of
locoregional recurrence.2 However, many studies have al-
ready concluded that sleeve lobectomy does not increase
the incidence of local and regional recurrence compared
with pneumonectomy; therefore, sleeve lobectomy should
be performed instead of pneumonectomy in patients with
NSCLC, regardless of their nodal status, whenever com-
plete resection can be achieved because it is a lung-saving
procedure with lower postoperative risks and is as curative
as pneumonectomy.4 In cases of wedge bronchoplastic lo-
bectomy, local and regional recurrences are also matters
of primary consideration. Most surgeons believe that both
tumor and nodal clearance are less satisfactory with wedge
bronchoplastic lobectomy than they are with sleeve lobec-
tomy; therefore, they assume that the incidence of local
and locoregional recurrence in wedge bronchoplastic lobec-
tomy is greater than that of sleeve lobectomy.5 In this study,
however, the incidence of local recurrence was 8.9% in
wedge bronchoplasty, which is comparable with the re-
ported data for sleeve lobectomy (5%-24%).11,12 If the
definition of local recurrence is limited to stump
recurrence, then the incidence of local recurrence was
only 5.2%. Regarding long-term survival, our results of
wedge bronchoplastic lobectomy were comparable with
previous reports of sleeve lobectomy (Table 3). Even in
the N2 cases, the 5-year overall survival was greater than
50%. In addition, freedom from local and locoregional re-
currence did not differ by nodal status. These results implyrdiovascular Surgery c Volume 143, Number 4 829
TABLE 3. Comparison of outcome between current study of wedge bronchoplastic lobectomy and previous studies of sleeve lobectomies
First author Year
No. of
patients
Bronchial
stenosis (%)
BPF
(%)
Operative
mortality (%)
5-yr overall survival (%) Local
recurrence (%)
R1
resection (%)All N0 N1 N2
Tedder6 1992 1915 5.0 3.5 7.5 — — — — 10.3 —
Van Schill15 1996 145 — — 4.8 46 62 29 31 20 —
Rea14 1997 217 2.3 2.3 6.2 49 72 36 22 8.7 —
Deslauriers5 2004 300 — — 2.7 54 66 50 19 16 —
Kim12 2005 49 4.0 2.0 6.1 53.7 74.8 51.5 — 24 6
Ludwig3 2005 116 — 6.9 4.3 39 56 38 24 — —
This study 2011 191 2.6 1.6 3.7 62.8 68.6 64.4 52.6 8.9 4.2
BPF, Bronchopleural fistula.
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choplastic lobectomy are satisfactory. Therefore, wedge
bronchoplastic lobectomy can be performed, regardless of
the nodal status, without compromising oncologic princi-
ples. If the complete dissection of suspicious positive lymph
nodes is possible, then nodal status is not a contraindication
for wedge bronchoplastic lobectomy.
Concerning the resection margins after wedge broncho-
plastic lobectomy, inconsistency between the frozen and
permanent sections was inevitable. In cases of incomplete
resection, however, other treatment modalities, such as ra-
diotherapy or photodynamic therapy, could be considered
after the operation. Also, regular and preemptive follow-
up by bronchoscopy is important for detecting early local
recurrence. Even if local recurrence is detected, a second
procedure or local treatments could be treatment options.
Furthermore, even when there is dysplasia or CIS in the re-
section margins, not all patients have local recurrence.
Wind and colleagues9 have reported the results of a meta-
analysis in which they concluded that the survival of pa-
tients with CIS at the bronchial resection margin was
comparable with the survival after a radical resection.
Regarding the surgical mortality, the operative mortality
rate for wedge bronchoplastic lobectomy in our study was
3.7%. These results are similar to the previously reported
operative mortalities for sleeve lobectomy (2.7%-7.5%)
(Table 3).13-16 In terms of surgical morbidity, wedge
bronchoplastic lobectomy is also a safer procedure than
sleeve lobectomy. The incidence of BPFs after sleeve
lobectomy has been reported to be approximately 5%,7
the incidence of BVFs has been reported to be from 0.9%
to 3.2%, and the incidence of late anastomotic strictures
has been reported to be from 2.3% to 5%.5,14,17
Compared with these previous sleeve lobectomy results,
the incidences of these common complications after
wedge bronchoplastic lobectomy are relatively low.
Nazari and coworkers18 assumed a correlation between
a better systemic blood supply to the distal portions of the
bronchus after bronchial wedge resection and better postop-
erative outcomes. In addition, BVFs, which are the most
devastating complication in sleeve and bronchoplastic lo-
bectomy, did not develop in this study. We believe that830 The Journal of Thoracic and Cardiovascular Surgboth the preserved blood supply to the distal bronchus and
the pericardial or pleural flap that covered the bronchoplasty
site played roles in preventing BVFs. Moreover, 2 of the 3
patients with BPFs recovered with only conservative treat-
ment. If a pericardial or pleural flap covers the broncho-
plasty site completely, any BPFs that occur can heal
through granulation tissues without surgical intervention.
Similar to sleeve lobectomy, however, several anasto-
motic complications can also develop after wedge broncho-
plastic lobectomy. As described earlier, mild or moderate
ischemia can develop after wedge bronchoplastic lobec-
tomy. In the process of healing from ischemia, granulation
tissues can grow at the bronchoplasty site, and these granu-
lation tissues can result in luminal narrowing. However, lu-
minal narrowing without near total obstruction is not
clinically significant. In contrast to circumferential stric-
tures after sleeve lobectomy, luminal narrowing after wedge
bronchoplastic lobectomy is not circumferential. The pa-
tency of the lumen can be preserved owing to the viable
remnant bronchus, even if luminal narrowing has devel-
oped. However, inner folding is one of the important surgi-
cal complications of performing a wedge bronchoplastic
lobectomy. This inner folding develops only after broncho-
plasty and finally results in luminal narrowing. To prevent
the ‘‘inner fold,’’ we create a wide wedge resection and su-
ture the edge of the bronchus obliquely. In some cases, we
add extra sutures to the remainder of the bronchus to make
an ‘‘outer fold’’ or to do the plication (Figure 1, B).
Limitations
This studyhad several limitations.Thepostoperative bron-
choscopic follow-up inspectionswere performed in only half
of the patients. Thus, the incidence of abnormal broncho-
scopic findings may have been underestimated. However,
we routinely performed intraoperative bronchoscopic evalu-
ations after the anastomosis. If severe anastomotic compli-
cations (such as BPFs or bronchial stenosis) developed,
they could be detected from the clinical symptoms. There-
fore, we believe that the rate of severe anastomotic compli-
cations in this article probably reflects the clinical
outcomes of wedge bronchoplastic lobectomy accurately.
Second, we did not compare the surgical outcomes ofery c April 2012
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lobectomy. Because this was a retrospective study, the tu-
mor characteristics of the sleeve lobectomy may have been
more aggressive than those of the wedge bronchoplastic
lobectomy. The 5-year overall survival and 5-year freedom
from locoregional recurrence between the wedge broncho-
plasty and sleeve lobectomy in our institute were added in
Figure E4. However, because of the small number of
sleeve lobectomy cases, the question of intent-to-treat,
and the lack of centrality of this comparison to this study,
we tried to emphasize the oncologic feasibility of wedge
bronchoplastic lobectomy for primary lung cancer.
CONCLUSIONS
Wedge bronchoplastic lobectomy for lung cancer shows
acceptable postoperative outcomes without compromising
the oncologic principles. It can be performed regardless of
nodal status and could be considered an appropriate alterna-
tive to sleeve lobectomy.
We are indebted to Dr Joon Seon Ryu at the National Cancer
Center for the illustrations.References
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FIGURE E1. CONSORT diagram of the patients in this study.
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FIGUREE2. The postoperative bronchoscopic findings. A, A normal finding after wedge bronchoplastic lobectomy. B,Mild ischemia at the bronchoplasty
site without luminal narrowing after a wedge bronchoplastic right upper lobectomy. C, Moderate ischemia and luminal narrowing at the bronchoplasty site
after a wedge bronchoplastic left upper lobectomy. In contrast to the circumferential stricture after a sleeve lobectomy, the remnant portion of the bronchus is
viable, and patency is preserved. D, Severe ischemia and necrosis at the bronchoplasty site after left upper bronchoplastic lobectomy. This lesion gradually
became pinpoint, and the patient eventually received balloon dilatation. (Arrow ¼ bronchoplasty site.)
FIGUREE3. The outcomes for the patients who showed dysplasia, carcinoma in situ and carcinoma in the permanent pathology reports.CIS,Carcinoma in
situ; BPF, bronchopleural fistula; Tx, therapy; RTx, radiotherapy; CTx, chemotherapy.
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FIGURE E4. Survival curves between wedge bronchoplasty and sleeve lobectomy. A, Overall survival according to the surgical approaches. B, Freedom
from locoregional recurrence according to the surgical approaches. CI, Confidence intervals.
TABLE E1. The agreement and disagreement between the frozen and permanent pathologic reports
Intraoperative frozen pathologic
reports
Permanent pathologic reports
() for malignancy Metaplasia Dysplsia CIS Carcinoma
() for malignancy (n ¼ 184) 175 2 2 4 1
Dysplasia (n ¼ 4)   3 1 
CIS (n ¼ 3)   1 2 
175 2 6 7 1
CIS, Carcinoma in situ.
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